Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239146 · ClinicalTrials.gov registry record · Phase 1
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02239146 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 43 participants.
The verdict
NCT02239146, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate the safety of escalating single doses of rFXIII (recombinant factor XIII, catridecacog) administered following first time myocardial revascularization requiring cardiopulmonary bypass (CPB).
Interventions
- DRUG placebo
- DRUG catridecacog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239146
The ClinicalTrials.gov registry entry for NCT02239146 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02239146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02239146 about?
NCT02239146 is a clinical study titled "Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass". This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate the safety of escalating single doses of rFXIII (recombinant factor XIII, catridecacog) administered following first time myocardial revascularization requiring cardiopulmonary bypass (CPB)...
What is the current status of trial NCT02239146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2005-10. Estimated completion is 2008-01.
What interventions are being tested in trial NCT02239146?
The interventions under investigation include: placebo (DRUG), catridecacog (DRUG).
Who is sponsoring clinical trial NCT02239146?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.